Identification of the crucial parameters regarding the efficacy of ribavirin therapy in Crimean–Congo haemorrhagic fever (CCHF) patients: a systematic review and meta-analysis
Objectives
Recently, ribavirin has been suggested as a therapeutic approach in Crimean–Congo haemorrhagic fever (CCHF) patients; however, there are controversial findings about its efficacy. In the current study, a meta-analysis was systematically performed to assess the effectiveness of ribavirin administration regarding CCHF patient survival and to explore the most important influential parameters for its efficacy.
Methods
All of the outcomes of the clinically studied CCHF patients who were treated with ribavirin were included in the meta-analysis.
Results
Overall, 24 studies met our criteria. Although the studies did not have high quality there was no heterogeneity and publication bias across studies. The results indicated that the administration of ribavirin to CCHF patients significantly decreased the mortality rate (by 1.7-fold) compared with those who did not receive this medication. Furthermore, it was found that the prescription of ribavirin in the initial phase of disease was more effective, and a delay in the start of treatment resulted in a 1.6-fold increase in mortality rate. In addition, interventional therapy resulted in an ∼2.3-fold reduction in the mortality rate of those who received ribavirin along with corticosteroids compared with those who were treated with ribavirin monotherapy.
Conclusions
This meta-analysis reveals that ribavirin should be considered as a crucial antiviral drug in the therapeutic approach used for CCHF patients, especially in early phases of the disease. Additionally, it seems that the administration of corticosteroids alongside ribavirin can play an effective role in alleviation of the disease status, particularly in haemorrhagic phases.
Top-30
Journals
|
1
2
|
|
|
PLoS Neglected Tropical Diseases
2 publications, 7.69%
|
|
|
Infection and Drug Resistance
2 publications, 7.69%
|
|
|
Nature Reviews Microbiology
1 publication, 3.85%
|
|
|
Frontiers in Immunology
1 publication, 3.85%
|
|
|
Infectious Diseases and Therapy
1 publication, 3.85%
|
|
|
Comparative Immunology, Microbiology and Infectious Diseases
1 publication, 3.85%
|
|
|
Molecular and Cellular Probes
1 publication, 3.85%
|
|
|
Pathogens
1 publication, 3.85%
|
|
|
Nucleosides, Nucleotides and Nucleic Acids
1 publication, 3.85%
|
|
|
Indian Journal of Medical Research
1 publication, 3.85%
|
|
|
International Journal of Infection
1 publication, 3.85%
|
|
|
Archives of Clinical Infectious Diseases
1 publication, 3.85%
|
|
|
Médecine et Maladies Infectieuses Formation
1 publication, 3.85%
|
|
|
VirusDisease
1 publication, 3.85%
|
|
|
American Journal of Tropical Medicine and Hygiene
1 publication, 3.85%
|
|
|
Virus Research
1 publication, 3.85%
|
|
|
Russian Chemical Reviews
1 publication, 3.85%
|
|
|
New Microbes and New Infections
1 publication, 3.85%
|
|
|
Therapeutic Advances in Infectious Disease
1 publication, 3.85%
|
|
|
Journal of Vector Borne Diseases
1 publication, 3.85%
|
|
|
Clinical Microbiology Reviews
1 publication, 3.85%
|
|
|
Expert Review of Anti-Infective Therapy
1 publication, 3.85%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
|
|
|
Elsevier
5 publications, 19.23%
|
|
|
Taylor & Francis
4 publications, 15.38%
|
|
|
Springer Nature
3 publications, 11.54%
|
|
|
Public Library of Science (PLoS)
2 publications, 7.69%
|
|
|
Brieflands
2 publications, 7.69%
|
|
|
Frontiers Media S.A.
1 publication, 3.85%
|
|
|
MDPI
1 publication, 3.85%
|
|
|
Scientific Scholar
1 publication, 3.85%
|
|
|
American Society of Tropical Medicine and Hygiene
1 publication, 3.85%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.85%
|
|
|
SAGE
1 publication, 3.85%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 3.85%
|
|
|
American Society for Microbiology
1 publication, 3.85%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.